Lilly CEO Sees Massive GLP-1 Demand

Ricks highlighted the immense potential for the obesity treatment market, noting that supply constraints remain the primary hurdle to wider adoption.

The company's new oral pill, Foundayo, saw nearly 1,400 prescriptions in its debut week, signaling strong consumer interest in non-injectable options.

Despite the rapid growth, the CEO emphasized that the industry's job is to ensure these life-changing medicines reach the patients who need them most.

Lilly is currently investing billions to expand its manufacturing capacity to meet the 'unprecedented' global demand.